-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Terns Pharma, Raises Price Target to $58

Benzinga·12/09/2025 17:34:25
Listen to the news
Oppenheimer analyst Jay Olson maintains Terns Pharma (NASDAQ:TERN) with a Outperform and raises the price target from $28 to $58.